Arbutus Biopharma Corp (ABUS) — QMA analysis

Sector: Healthcare · Market cap: $769M · Price: $4,21 · Data as of 2026-10-22

/100

Composite grade

Higher score than 86% of 22,733 tracked stocks

A composite score of 56/100 places Arbutus Biopharma Corp in the neutral band, higher score than 86% of 22,733 tracked stocks. The highest-scoring layer is Analysts / transcripts; the lowest is Insider activity.

Analytical score, not investment advice. No score is an instruction or a guarantee. Past performance ≠ future results.

Free registration, no card — trial full access to ABUS, then the free plan

What 11 data layers say about ABUS

The composite fuses insiders, congressional trades, institutional 13F positions, fundamentals, momentum, seasonality and more into a single number.

Layer	Score	What it shows
Fundamental value (FVS)	87/100	Fundamental value: 87/100 — well above average.
Earnings quality (EQS)	40/100	Earnings quality: 40/100 — below average.
Technical trend (TSS)	46/100	Technical trend: 46/100 — neutral, no clear direction.
Relative strength (RS)	29/100	Relative strength: 29/100 — well below average.
Momentum (USS)	40/100	Momentum: 40/100 — below average.
Insider activity (IAS)	10/100	Insider activity: 10/100 — well below average.
Off-exchange trading (FINRA) / large flows (WHS)	37/100	Off-exchange trading (FINRA) / large flows: 37/100 — below average.
Institutional 13F (IFS)	65/100	Institutional 13F: 65/100 — above average.
News sentiment (NSS)	52/100	News sentiment: 52/100 — neutral, no clear direction.
Analysts / transcripts (ATS)	90/100	Analysts / transcripts: 90/100 — well above average.
Catalysts (XS)	72/100	Catalysts: 72/100 — above average.

What does the QMA model currently show for Arbutus Biopharma Corp?

The composite score is a research starting point, not an instruction. What matters is layer confluence — whether the layers point in the same direction.

For ABUS the layers diverge — some score high (Analysts / transcripts), others low (Insider activity). The divergence is itself information: the model does not give a clear-cut picture. The score is an input into your own research, not a recommendation.

ABUS insider & smart money activity

Over the recent period we record 8 reported insider purchases and 12 sales for ABUS: mixed picture. A description of the data layer, not an instruction.

How ABUS compares

Similar stocks from the same sector:

ABUS vs TLRY ABUS vs MDXG ABUS vs IRWD

Frequently asked questions

What is the composite score for ABUS stock?

56/100 (B) — Data as of 2026-10-22.

Are insiders buying ABUS stock?

Over the recent period, reported: purchases 8, sales 12 (purchases $2.48M, sales $4.96M). Insider activity: mixed picture — a description of reported data, not a trade instruction.

Where can I see live ABUS data?

Live ABUS data and the full screener are part of full access. Registration is free with no card — trial full access, then the free plan with a delayed data sample.

Free registration, no card — trial full access, then the free plan

Open ABUS detail →

Data from SEC and public markets. QMA is an analytical tool, not a registered investment advisor. No content on this page is investment advice or an instruction to buy or sell. Past performance does not guarantee future results.

⚠️ Important Notice: QMA is an analytical and educational tool, not investment advice. Scores, detections and ratings are descriptive, not buy/sell instructions. QMA is not a registered investment advisor (SEC / FINRA / MiFID II / ČNB). Consult a licensed financial advisor before any investment. Past performance does not guarantee future results; all investments carry the risk of capital loss.

Operator: Jaroslav Vojtášek · IČO: 48783447 · Place of business: U Jízdárny 577, 747 64 Velká Polom, Czech Republic · Register: Sole trader registered in the Czech Trade Licensing Register · E-mail: [email protected]